Sara Yumeen

Sara Yumeen

Auto-generated profile, based on publicly available information

Sara Yumeen

Department of Dermatology Yale School of Medicine New Haven CT USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
STSébastien Tabariès
Sébastien Tabariès
MAMatthew G. Annis
Matthew G. Annis
ANTHOULA LAZARISANTHOULA LAZARIS
ANTHOULA LAZARIS
SPStephanie K. Petrillo
Stephanie K. Petrillo
JHJennifer Huxham
Jennifer Huxham
PSPeter Siegel
Peter Siegel
Claudin-2 promotes breast cancer liver metastasis by enabling seeding and early cancer cell survival. We now demonstrate that Claudin-2 is functionally required for colorectal cancer liver metastasis and that Claudin-2 expression in primary colorectal cancers is associated with poor overall and liver metastasis-free survival. We have examined the role of Claudin-2, and other claudin family members, as potential prognostic biomarkers of the desmoplastic and replacement histopathological growth pattern associated with colorectal cancer liver metastases. Immunohistochemical analysis revealed higher Claudin-2 levels in replacement type metastases when compared to those with desmoplastic features. In contrast, Claudin-8 was highly expressed in desmoplastic colorectal cancer liver metastases. Similar observations were made following immunohistochemical staining of patient-derived xenografts (PDXs) that we have established, which faithfully retain the histopathology of desmoplastic or replacement type colorectal cancer liver metastases. We provide evidence that Claudin-2 status in patient-derived extracellular vesicles may serve as a relevant prognostic biomarker to predict whether colorectal cancer patients have developed replacement type liver metastases. Such a biomarker will be a valuable tool in designing optimal treatment strategies to better manage patients with colorectal cancer liver metastases.

21 May 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
SYSara Yumeen
Sara Yumeen
FMFatima N. Mirza
Fatima N. Mirza
JLJulia M. Lewis
Julia M. Lewis
AKAmber Loren O. King
Amber Loren O. King
SKSa Rang Kim
Sa Rang Kim
MGMichael Girardi
Michael Girardi
Cutaneous T-cell lymphoma (CTCL) is a malignancy of skin-homing T lymphocytes that is more likely to involve the peripheral blood in advanced stages. For such patients with advanced disease, there are few available systemic treatment options, and prognosis remains poor. Exome sequencing studies of CTCL have suggested therapeutic targets, including within the JAK/STAT pathway, but JAK inhibition strategies may be limited by patient-specific mutational status. Because our recent research has highlighted the potential roles of single and combination approaches specifically using BCL2, bromodomain and extra-terminal domain (BET), and histone deacetylase (HDAC) inhibition, we aimed to investigate the effects of JAK inhibition on CTCL cells and established CTCL cell lines when paired with these and other targeting agents. Peripheral blood malignant CTCL isolates exhibited differential responses to JAK inhibition, with JAK2 expression levels negatively correlating to 50% inhibitory concentration (IC50) values. Regardless of single-agent sensitivity, JAK inhibition potentiated malignant cell cytotoxicity in combination with BCL2, BET, HDAC, or proteasome inhibition. Combination inhibition of JAK and BCL2 showed the strongest potentiation of CTCL cytotoxicity, driven by both intrinsic and extrinsic apoptosis pathways. JAK inhibition decreased expression of BCL2 in the high-responder samples, suggesting a putative mechanism for this combination activity. These results indicate that JAK inhibition may have major effects on CTCL cells, and that combination strategies using JAK inhibition may allow for more generalized cytotoxic effects against the malignant cells from patients with CTCL. Such preclinical assessments help inform prioritization for combination targeted drug approaches for clinical utilization in the treatment of CTCL.

15 March 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
George KroumpouzosGeorge Kroumpouzos
George Kroumpouzos
Maria-Eleni ParoikakiMaria-Eleni Paroikaki
Maria-Eleni Paroikaki
SYSara Yumeen
Sara Yumeen
SBShashank Bhargava
Shashank Bhargava
Eleftherios MylonakisEleftherios Mylonakis
Eleftherios Mylonakis
Because of the increasing emergence of cutaneous reactions from COVID-19 vaccines worldwide, we investigated the published reports of these complications. We searched the PubMed, Google Scholar, and Scopus databases and the preprint server bioRxiv for articles on cutaneous complications linked to mRNA-1273 (Moderna), BNT162b2 (Pfizer–BioNTech), and AZD1222 (AstraZeneca–Oxford University) vaccines published until 30 September 2021. Eighty studies describing a total of 1415 reactions were included. Cutaneous reactions were more prevalent in females (81.6%). Delayed large local reactions were the most common complication (40.4%), followed by local injection site reactions (16.5%), zoster (9.5%), and urticarial eruptions (9.0%). Injection site and delayed large local reactions were predominantly caused by the mRNA-1273 vaccine (79.5% and 72.0%, respectively). BNT162b2 vaccination was more closely linked to distant reactions (50.1%) than mRNA-1273 (30.0%). Zoster was the most common distant reaction. Of reactions with adequate information for both vaccine doses, 58.3% occurred after the first dose only, 26.9% after the second dose only, and 14.8% after both doses. Overall, a large spectrum of cutaneous reaction patterns occurred following the COVID-19 vaccination. Most were mild and without long-term health implications. Therefore, the occurrence of such dermatologic complications does not contraindicate subsequent vaccination.

2 August 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
FMFatima N. Mirza
Fatima N. Mirza
RLRachel Lim
Rachel Lim
SYSara Yumeen
Sara Yumeen
SWSamer Wahood
Samer Wahood
BZBashar Zaidat
Bashar Zaidat
TLTiffany J. Libby
Tiffany J. Libby

9 September 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JLJulia M. Lewis
Julia M. Lewis
PMPatrick F. Monico
Patrick F. Monico
FMFatima N. Mirza
Fatima N. Mirza
SXSuzanne Xu
Suzanne Xu
SYSara Yumeen
Sara Yumeen
MGMichael Girardi
Michael Girardi
Significance: Ultraviolet (UV) exposure from the sun is the greatest risk factor for skin cancer. Toward preventive strategies, we elucidated the immune pathways critical to skin cancer development and identified specific cells and signals associated with mutated skin cell growth. UV light and Langerhans cells cooperate to induce lymphoid cells that produce interleukin-22 locally and are associated with mutant skin cell growth. This effect is highly dependent on the differentiation factor RORγt that can be inhibited with a topical agent. Such skin cancer–supporting immune cells were identified with distinctive markers: RORγt+ Sca-1+ CD103+ ICOS+ CD2+/−CCR6+ intracellular CD3+. Together, these data elucidate key immune components of UV-induced skin cancer that may represent targets for skin cancer prevention.